Given the fact that different types of dementia can be diagnosed only postmortem or when the disease has progressed enough to cause irreversible damage to certain brain areas, there has been an increasing need for the development of sensitive and reliable methods that can detect early preclinical forms of dementia, before the symptoms have even appeared. Ideally, such a method would have the following characteristics: to be inexpensive, sensitive and specific, Non-invasive, fast and easily accessible. The ophthalmologic examination and especially the study of the retina, has caught the attention of many researchers, as it can provide a lot of information about the CNS and it fulfills many of the aforementioned criteria. Since the introduction of the non-invasive optical coherence tomography (OCT) and the newly developed modality OCT-angiography (OCT-A) that can demonstrate the structure and the microvasculature of the retina and choroid, respectively, there have been promising results regarding the value of the ophthalmologic examination in the early diagnosis of Alzheimer’s disease. In this review paper, we summarize and discuss the ocular findings in patients with cognitive impairment disorders and we highlight the importance of the ophthalmologic examination to the diagnosis of these disorders.
GanguliMBlackerDBlazerDG, et al. Classification of neurocognitive disorders in DSM-5: a work in progress. Am J Geriatr Psychiatry2011; 19(3): 205–210.
2.
JindalV. Interconnection between brain and retinal neurodegenerations. Mol Neurobiol2015; 51(3): 885–892.
3.
CsőszÉBorossPCsutakA, et al. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. J Proteomics2012; 75(7): 2196–2204.
4.
DuteskuRMLiQXCrowstonJ, et al. Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease. Graefes Arch Clin Exp Ophthalmol2009; 247(9): 1213–1221.
5.
GoldsteinLEMuffatJAChernyRA, et al. Cytosolic beta-amyloid deposition and supranuclear cataract in lenses from people with Alzheimer’s disease. Lancet2003; 361(9365): 1258–1265.
JackCRJrAlbertMSKnopmanDS, et al. Introduction to the recommendations from the national institute on aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7(3): 257–262.
8.
FroimanPCDantasPEC. Assessment of visual acuity in patients with dementia using teller acuity cards. Strabismus2013; 21(2): 93–97.
9.
MarquieMCastilla-MartíMValeroS, et al. Visual impairment and cognitive decline: experience in a memory clinic. Sci Rep2019; 9(1): 8698.
10.
RizzoMAndersonSWDawsonJ, et al. Vision and cognition in Alzheimer’s disease. Neuropsychologia2000; 38(8): 1157–1169.
11.
Salobrar-GarciaEde HozRRojasB, et al. Ophthalmologic psychophysical tests support OCT findings in mild Alzheimer’s disease. J Ophthalmol2015; 2015: 736949.
12.
MurgatroydCPrettymanR. An investigation of visual hallucinosis and visual sensory status in dementia. Int J Geriatr Psychiatry2001; 16(7): 709–713.
13.
LeylandLABremnerFDMahmoodR, et al. Visual tests predict dementia risk in Parkinson disease. Neurol Clin Pract2020; 10(1): 29–39.
14.
Metzler-BaddeleyCBaddeleyRJLovellPG, et al. Visual impairment in dementia with Lewy bodies and posterior cortical atrophy. Neuropsych2010; 24(1): 35–48.
15.
PaikJSHaMJungYH, et al. Low vision and the risk of dementia: a nationwide population-based cohort study. Sci Rep2020; 10(1): 9109.
16.
GilmoreCGGrothKEThomasCW. Stimulus contrast and word reading speed in Alzheimer’s disease. Exp Aging Res2005; 3(1): 15–33.
17.
RisacherSLWudunnDPepinSM, et al. Visual contrast sensitivity in Alzheimer’s disease, mild cognitive impairment, and older adults with cognitive complaints. Neurobiol Aging2013; 34(4): 1133–1144.
18.
PoloVRodrigoMJGarcia-MartinE, et al. Visual dysfunction and its correlation with retinal changes in patients with Alzheimer’s disease. Eye2017; 31(7): 1034–1041.
19.
RisacherSLWuDunnDTallmanEF, et al. Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. Brain Communications2020; 2(1): fcaa019.
20.
SalamoneGDi LorenzoCMostiS, et al. Color discrimination performance in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord2009; 27(6): 501–507.
21.
PacheMSmeetsCHGasioPF, et al. Colour vision deficiencies in Alzheimer’s disease. Age Ageing2003; 32(4): 422–426.
22.
FlaniganPMKhosraviMALeverenzJB, et al. Color vision impairment differentiates Alzheimer dementia from dementia with lewy bodies. J Geriatr Psychiatry Neurol2018; 31(2): 97–102.
23.
TrickGLTrickLRMorrisP, et al. Visual field loss in senile dementia of the Alzheimer’s type. Neurology1995; 45(1): 68–74.
24.
WhittakerKWBurdonMAShahP. Visual field loss and Alzheimer’s disease. Eye2002; 16(2): 206–208.
25.
ValentiDA. Alzheimer’s disease: screening biomarkers using frequency doubling technology visual field. ISRN Neurol2013; 2013: 989583.
26.
BayerAUKellerONFerrariF, et al. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease. Am J Ophthalmol2002; 133(1): 135–137.
27.
MendezMFCherrierMMMeadowsRS. Depth perception in Alzheimer’s disease. Percept Mot Skills1996; 83(3 Pt 1): 987–995.
28.
LeeCNKoDSuhYW, et al. Cognitive functions and stereopsis in patients with Parkinson’s disease and Alzheimer’s disease using 3-dimensional television: a case controlled trial. PLoS One2015; 10(3): e0123229.
CrawfordTJDevereauxAHighamS, et al. The disengagement of visual attention in Alzheimer’s disease: a longitudinal eye-tracking study. Front Aging Neurosci2015; 7: 118.
31.
LevyNKLavidorMVakilE. Prosaccade and antisaccade paradigms in persons with Alzheimer’s disease: a meta-analytic review. Neuropsychol Rev2018; 28(1): 16–31.
32.
LagunDManzanaresCZolaSM, et al. Detecting cognitive impairment by eye movement analysis using automatic classification algorithms. J Neurosci Methods2011; 201(1): 196–203.
33.
WilcocksonTDWMardanbegiDXiaB, et al. Abnormalities of saccadic eye movements in dementia due to Alzheimer’s disease and mild cognitive impairment. Aging (Albany NY)2019; 11(15): 5389–5398.
34.
ZhouLZhaoSZKohSK, et al. In-depth analysis of the human tear proteome. J Proteomics2012; 75(13): 3877–3885.
35.
KalloGEmriMVargaZ, et al. Changes in the chemical barrier composition of tears in Alzheimer’s disease reveal potential tear diagnostic biomarkers. PLoS One2016; 11(6): e0158000.
36.
van den BergMMJKrauskopfJRamaekersJG, et al. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Prog Neurobiol2020; 185: 101732.
37.
KennyAJiménez-MateosEMZea-SevillaMA, et al. Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer’s disease. Sci Rep2019; 9(1): 15437.
38.
ComogluSSGuvenHAcarM, et al. Tear levels of tumor necrosis factor-alpha in patients with Parkinson’s disease. Neurosci Lett2013; 553: 63–67.
39.
Hamm-AlvarezSFOkamotoCTJangaSR, et al. Oligomeric α-synuclein is increased in basal tears of Parkinson’s patients. Biomark Med2019; 13(11):941–952.
40.
StixBLeberMBLeonardMC, et al. Hereditary lattice corneal dystrophy is associated with corneal amyloid deposits enclosing C-terminal fragments of keratoepithelin. Invest Ophthalmol Vis Sci2005; 46(4): 1133–1139.
41.
FrederiksePHZiglerJSJr.Presenilin expression in the ocular lens. Curr Eye Res1998; 17: 947–952.
42.
ChoiSILeeBWooJH, et al. APP processing and metabolism in corneal fibroblasts and epithelium as a potential biomarker for Alzheimer’s disease. Exp Eye Res2019; 182: 167–174.
43.
OrnekNDagEOrnekK. Corneal sensitivity and tear function in neurodegenerative disorders. Curr Eye Res2015; 40(4): 423–428.
44.
PonirakisGAl HamadHSankaranarayananA, et al. Association of corneal nerve fiber measures with cognitive function in dementia. Ann Clin Transl Neurol2019; 6(4): 689–697.
45.
DavsonH. A comparative study of the aqueous humour and cerebrospinal fluid in the rabbit. J Physiol1955; 129(1): 111–133.
46.
InoueTKawajiTTaniharaH. Elevated levels of multiple biomarkers of Alzheimer’s disease in the aqueous humor of eyes with open-angle glaucoma. Invest Ophthalmol Vis Sci2013; 54(8): 5353–5358.
47.
JanciauskieneSKrakauT. Alzheimer’s peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome. Doc Ophthalmol2003; 106(3): 215–223.
48.
KwakDEKoTKohHS, et al. Alterations of aqueous humor Aβ levels in Aβ-infused and transgenic mouse models of Alzheimer disease. PLoS One2020; 15(1): e0227618.
49.
ChougulePSNajjarRPFinkelsteinMT, et al. Light-induced pupillary responses in Alzheimer’s disease. Front Neurol2019; 10: 360.
50.
MicieliGTassorelliCMartignoniE, et al. Disordered pupil reactivity in Parkinson’s disease. Clin Auton Res1991; 1(1): 55–58.
51.
KahyaMMoonSLyonsKE, et al. Pupillary response to cognitive demand in Parkinson’s disease: a pilot study. Front Aging Neurosci2018; 10: 90.
52.
DehghaniCFrostSJayasenaR, et al. Ocular biomarkers of Alzheimer’s disease: the role of anterior eye and potential future directions. Invest Ophthalmol Vis Sci2018; 59(8): 3554–3563.
53.
MichaelROttoCLenferinkA, et al. Absence of amyloid-beta in lenses of Alzheimer patients: a confocal Raman microspectroscopic study. Exp Eye Res2014; 119: 44–53.
54.
MoncasterJAPinedaRMoirRD, et al. Alzheimer’s disease amyloid-beta links lens and brain pathology in down syndrome. PLoS One2010; 5(5): e10659.
55.
BeiLShuiYBBaiF, et al. A test of lens opacity as an indicator of preclinical Alzheimer disease. Exp Eye Res2015; 140: 117–123.
56.
SadowskyCHKerbageCTariotPN, et al. Diagnosis of Alzheimer’s disease through the eye and its correlation with cognitive tests and brain imaging. JSM Alzheimer’s Dis Relat Dement2014; 1(2): 1008.
57.
WrightLMSteinTDJunG, et al. Association of cognitive function with amyloid-β and tau proteins in the vitreous humor. J Alzheimers Dis2019; 68(4): 1429–1438.
58.
SubramanianMLVigVChungJ, et al. Neurofilament light chain in the vitreous humor of the eye. Alzheimers Res Ther2020; 12(1): 111.
59.
CsincsikLMacGillivrayTJFlynnE, et al. Peripheral retinal imaging biomarkers for Alzheimer’s disease: a pilot study. Ophthalmic Res2018; 59: 182–192.
60.
UkalovicKCaoSLeeS, et al. Drusen in the peripheral retina of the Alzheimer’s eye. Curr Alzheimer Res2018; 15(8): 743–750.
61.
HeringaSMBouvyWHvan den BergE, et al. Associations between retinal microvascular changes and dementia, cognitive functioning, and brain imaging abnormalities: a systematic review. J Cereb Blood Flow Metab2013; 33(7): 983–995.
62.
CheungCYChenCWongTY. Ocular fundus photography as a tool to study stroke and dementia. Semin Neurol2015; 35(5): 481–490.
63.
de JongFJSchrijversEMIkramMK, et al. Retinal vascular caliber and risk of dementia: the Rotterdam study. Neurology2011; 76(9): 816–821.
64.
HuangDSwansonEALinCP, et al. Optical coherence tomography. Science1991; 254(5035): 1178–1181.
65.
KimJIKangBH. Decreased retinal thickness in patients with Alzheimer’s disease is correlated with disease severity. PLos One2019; 14(11): e0224180.
66.
PaquetCBoissonnotMRogerF, et al. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett2007; 420(2): 97–99.
67.
IseriPKAltinasÖTokayT, et al. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroopthalmol2006; 26(1): 18–24.
68.
Garcia-MartinESRojasBRamirezAI, et al. Macular thickness as a potential biomarker of mild Alzheimer’s disease. Ophthalmology2014; 21(5): 1149–1151.
69.
GaoLLiuYLiX, et al. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. Arch Gerontol Geriatr2015; 60(1): 162–167.
70.
AlmeidaALMPiresLAFigueiredoEA, et al. Correlation between cognitive impairment and retinal neural loss assessed by swept-source optical coherence tomography in patients with mild cognitive impairment. Alzheimers Dement (Amst)2019; 11: 659–669.
71.
Gimenez-CastejonDGomez-GallegoMMartinez-MartinezML, et al. How far reaches earliness of optical coherence tomography in cognitive impairment. Rev Neurol2016; 63(1): 5–10.
72.
MarquieMValeroSCastilla-MartiM, et al. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: fundacio ACE healthy brain initiative. Alzheimers Res Ther2020; 12(1): 37.
73.
AydinTSUmitDNurOM, et al. Optical coherence tomography findings in Parkinson’s disease. KJMS2018; 34(3): 166–171.
74.
SenguptaPDuttaKGhoshS, et al. Optical coherence tomography findings in patients of Parkinson’s disease: an Indian perspective. Ann Indian Acad Neurol2018; 21(2): 150–155.
75.
ElkhatibTHMHashimNAEmadEM, et al. Optical coherence tomography and cognitive dysfunction in Parkinson disease. Egypt J Neurol Psychiatry Neurosurg2019; 55: 52.
76.
KimBJIrwinDJSongD, et al. Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology2017; 89(15): 1604–1611.
77.
FerrariLHuangSCMagnaniG, et al. Optical coherence tomography reveals retinal neuroaxonal thinning in frontotemporal dementia as in Alzheimer’s disease. J Alzheimers Dis2017; 56(3): 1101–1107.
78.
Murueta-GoyenaADel PinoRReyeroP, et al. Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases. Mov Disord2019; 34(9): 1315–1324.
79.
KerstenHMDanesh-MeyerHVKilfoyleDH, et al. Optical coherence tomography findings in Huntington’s disease: a potential biomarker of disease progression. J Neurol2015; 262(11): 2457–2465.
80.
KoustenisAHarrisAGrossJ, et al. Optical coherence tomography angiography: an overview of the technology and an assessment of applications for clinical research. Br J Ophthalmol2017; 101(1): 16–20.
81.
O’ BryhimBEApteRSKungN, et al. Association of preclinical Alzheimer disease with optical coherence tomography angiography findings. JAMA Ophthalmol2018; 136(11): 1242–1248.
82.
LahmeLEsserELMihailovicN, et al. Evaluation of ocular perfusion in Alzheimer’s disease using optical coherence tomography angiography. J Alzheimers Dis2018; 66(4): 1745–1752.
83.
BulutMKurtuluşFGözkayaO, et al. Evaluation of optical coherence tomography angiographic findings in Alzheimer’s type dementia. Br J Ophthalmol2018; 102(2): 233–237.
84.
GrewalDSPolascikBWHoffmeyerGC, et al. Assessment of differences in retinal microvasculature using OCT angiography in Alzheimer’s disease: a twin discordance report. Ophthalmic Surg Lasers Imaging Retina2018; 49(6): 440–444.
85.
ZhangYSZhouNKnollBM, et al. Parafoveal vessel loss and correlation between peripapillary vessel density and cognitive performance in amnestic mild cognitive impairment and early Alzheimer’s disease on optical coherence tomography angiography. PLos One2019; 14(4): e0214685.
86.
YoonSPThompsonACPolascikBW, et al. Correlation of OCTA and volumetric MRI in mild cognitive impairment and Alzheimer’s disease. Ophthalmic Surg Lasers Imaging Retina2019; 50(11): 709–718.
87.
CriscuoloCCennamoGMontorioD, et al. Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography. PLoS One2020; 15(6): e0233975.
88.
KwapongWRYeHPengC, et al. Retinal microvascular impairment in the early stages of Parkinson’s disease. Invest Ophthalmol Vis Sci2018; 59(10): 4115–4122.
89.
ShiCChenYKwapongWR, et al. Characterization by fractal dimension analysis of the retinal capillary network in Parkinson disease. Retina2020; 40(8): 1483–1491.
90.
LeeJYKimJPJangH, et al. Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases. Alzheimers Res Therapy2020; 12(1): 73.
SauerLGensureRHAndersenKM, et al. Patterns of fundus autofluorescence lifetimes in eyes of individuals with nonexudative age-related macular degeneration. Invest Ophthalmol Vis Sci2018; 59(4): AMD65–AMD77.
93.
SauerLGensureRHHammerM, et al. Fluorescence lifetime imaging ophthalmoscopy (FLIO): a novel way to assess macular telangiectasia type 2. Ophthalmol Retina2017; 2(6): 587–598.
94.
DysliSWolfSZinkernagelMS. Fluorescence lifetime imaging in retinal artery occlusion. Invest Ophthalmol Vis Sci2015; 56(5): 3329–3336.
95.
DysliCWolfSHatzK, et al. Fluorescence lifetime imaging in stargardt disease: potential marker for disease progression. Invest Ophthalmol Vis Sci2016; 57: 832–841.
96.
SchweitzerDDeutschLKlemmM, et al. Fluorescence lifetime imaging ophthalmoscopy in type 2 diabetic patients who have no signs of diabetic retinopathy. J Biomed Opt2015; 20: 61106.
97.
SaddaSRBorrelliEFanW, et al. A pilot study of fluorescence lifetime imaging ophthalmoscopy in preclinical Alzheimer’s disease. Eye2019; 33: 1271–1279.
98.
ChenMDuZYZhengX, et al. Use of curcumin in diagnosis, prevention, and treatment of Alzheimer’s disease. Neural Regen Res2018; 13(4): 742–752.
99.
SidiqiAWahlDLeeS, et al. In vivo retinal fluorescence imaging with curcumin in an Alzheimer mouse model. Front Neurosci2020; 14: 713.
100.
WebbRHHughesGW. Scanning laser ophthalmoscope. IEEE Trans Biomed Eng1981; 28(7): 488–492.
101.
RoordaAWilliamsDR. The arrangement of the three cone classes in the living human eye. Nature1999; 397(6719): 520–522.
102.
ZhangBLiNKangJ, et al. Adaptive optics scanning laser ophthalmoscopy in fundus imaging, a review and update. Int J Ophthalmol2017; 10(11): 1751–1758.
103.
MeyerHVDBirchHKuJYF, et al. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology2006; 67(10): 1852–1854.
104.
ZhangYSOnishiACZhouN, et al. Characterization of inner retinal hyperreflective alterations in early cognitive impairment on adaptive optics scanning laser ophthalmoscopy. Invest Ophthalmol Vis Sci2019; 60(10): 3527–3536.
105.
GharbiyaMTrebbastoniAParisiF, et al. Choroidal thinning as a new finding in Alzheimer’s disease: evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis2014; 40(4): 907–917.
106.
BayhanHABayhanSACelikbilekA, et al. Evaluation of chorioretinal thickness changes in Alzheimer’s disease using spectral-domain optical coherence tomography. Clin Exp Ophthalmol2015; 43(2): 145–151.
107.
AsanadSRoss-CisnerosFNBarronE, et al. The retinal choroid as an oculovascular biomarker for Alzheimer’s dementia: a histopathological study in severe disease. Alzheimers Dement2019; 11: 775–783.
108.
BulutMYamanAErolMK, et al. Choroidal thickness in patients with mild cognitive impairment and Alzheimer’s type dementia. J Ophthalmol2016; 2016: 7291257.
109.
López-de-EguiletaACerveróARuizdeSabandoA, et al. Evaluation of choroidal thickness in prodromal Alzheimer’s disease defined by amyloid PET. PLoS One2020; 15(9): e0239484.
110.
RobbinsCBGrewalDSThompsonAC, et al. Choroidal structural analysis in Alzheimer’s disease, mild cognitive impairment, and cognitively healthy controls. Am J Ophthalmol2021; 223: 359–367.
111.
EraslanMCermanEYildiz BalciS, et al. The choroid and lamina cribrosa is affected in patients with Parkinson’s disease: enhanced depth imaging optical coherence tomography study. Acta Ophthalmol2016; 94(1): 68–75.
112.
MoschosMMChatziralliIP. Evaluation of choroidal and retinal thickness changes in Parkinson’s disease using spectral domain optical coherence tomography. Semin Ophthalmol2018; 33(4): 494–497.
113.
StatueMObisJAlarciaR, et al. Retinal and choroidal changes in patients with Parkinson’s disease detected by swept-source optical coherence tomography. Curr Eye Res2018; 43(1): 109–115.
114.
Amisha MalikPPathaniaM, et al. Overview of artificial intelligence in medicine. J Family Med Prim Care2019; 8(7): 2328–2331.
115.
LiuXChenKWuT, et al. Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer’s disease. Transl Res2018; 194: 56–67.
116.
TianJSmithGGuoH, et al. Modular machine learning for Alzheimer’s disease classification from retinal vasculature. Sci Rep2021; 11(1): 238.
117.
WiselyEWangDHenaoR, et al. Convolutional neural network to identify symptomatic Alzheimer’s disease using multimodal retinal imaging. Br J Ophthalmol. Epub ahead of print 26 November 2020. DOI: 10.1136/bjophthalmol-2020-317659.
118.
SoucyJPChevrefilsCSylvestreJP, et al. An amyloid ligand-free optical retinal imaging method to predict cerebral amyloid pet status. Alzheimer Dement2018; 14(7): P158.
119.
SandeepCSKumarSAMahadevanK, et al. Analysis of MRI and OCT images for early diagnosis of Alzheimers disease using wavelet networks. AMSE J Lect Model Simul2017; 2: 31–40.
